Company news: Warner Chilcott, Abbott Labs, Pfizer

Share this article:

FDA approved Warner Chilcott's Atelvia (risedronate sodium) delayed release tablets, billed as a next generation Actonel. Atelvia contains the same active ingredient as Actonel, but a different delivery mechanism. 

The US Supreme Court ruled in favor of 123 women in Minnesota who developed breast cancer after taking hormone replacement treatments, allowing those women to sue pharmaceutical manufacturers responsible for developing the treatments in a state court. Companies being sued by the women include Pfizer, Teva, J&J, Novartis, Abbott and Watson.

Abbott Laboratories pulled its Meridia (sibutramine) diet pill off the market due to increased risk of heart and stroke. “Meridia's continued availability is not justified when you compare the very modest weight loss that people achieve on this drug, to their risk of heart attack or stroke,” said John Jenkins, director of the office of new drugs in FDA's Center for Drug Evaluation and Research. Meridia had been on the market for nearly 13 years.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.